Moreover, although pharmacological treatments for COVID-19 might also have impacted the sFlt-1/PlGF level, none of the patients infected with SARS-CoV-2 had received low-molecular-weight heparin or specific anti-inflammatory drugs before the samples were collected. This evidence concerns the gene PGF and COVID-19.